RE:RE:If you haven’t listened to Earnings call…Thanks for posting the link. Interesting read. Definitely on solid footing but nothing that's going to trigger any kind of explosive growth in the share price, especially fromthe pharma side.
As Keith discussed previously, pharmaceutical revenue is a longer-term strategy and will take time to pay off as clinical trials progress and applications make their way through the long-term process of approvals.
Slow and steady climb probably starting next earnings.